NEKTAR THERAPEUTICS - 8-K Filing

Nektar Therapeutics enters quiet period ahead of Phase 2b REZOLVE-AA study data announcement (Items: 7.01 Regulation FD, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $NKTR

Read the full article at SEC EDGAR

More Regulatory news